Format

Send to

Choose Destination
Clin Cancer Res. 2018 Aug 1;24(15):3483-3485. doi: 10.1158/1078-0432.CCR-18-1114. Epub 2018 May 25.

Neratinib: Inching Up on the Cure Rate of HER2+ Breast Cancer?

Author information

1
Department of Medicine, UT Southwestern Medical Center, Dallas, Texas.
2
Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
3
Department of Medicine, UT Southwestern Medical Center, Dallas, Texas. carlos.arteaga@utsouthwestern.edu.
4
Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas.

Abstract

Neratinib was recently approved by the FDA for extended adjuvant treatment of HER2+ breast cancer. The ExteNET trial showed improvement in invasive disease-free survival (iDFS) in the neratinib arm compared with placebo. The benefit was more pronounced in patients with estrogen receptor-positive (ER+)/HER2+ tumors, suggesting bidirectional cross-talk between the ER and HER pathways. Clin Cancer Res; 24(15); 3483-5. ©2018 AACRSee related article by Singh et al., p. 3486.

PMID:
29802101
DOI:
10.1158/1078-0432.CCR-18-1114
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center